Author

Emir Hadzijusufovic

University of Veterinary Medicine ViennaORCID 0000-0001-7409-4204Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Assay:DNA methylation· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Peter ValentiD· 2 shared Aleksandr IanevskiiD· 1 shared Alfonso BellacosaiD· 1 shared Anna OrlovaiD· 1 shared Anna SchönbichleriD· 1 shared Anna-Mariya Kukuyan· 1 shared Bac Viet LeiD· 1 shared Brian J.P. HuntlyiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Peter ValentORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Reports MedicinePeer-reviewedMar 1, 2026

Pol is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells

Bac Viet Le, Umeshkumar M. Vekariya, Monika Maria Toma…·Tomasz Skórski

This study identifies Polθ as a therapeutic target in DNMT3A-mutated leukemia by showing its essential role in DNA repair and replication fork restart, and demonstrates that its inhibition enhances standard therapies.

1 citation

humanDNA methylation

𝕏 PostBluesky

Cancer BiologyHemaSpherePeer-reviewedNov 28, 2024

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

Daniel Pölöske, Helena Sorger, Anna Schönbichler…·Richard Moriggl

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

7 citations

humanexperimental assay

𝕏 PostBluesky